Evoke Pharma, Inc announced that the US Patent and Trademark Office (USPTO) issued US Patent No. 11,813,231 titled "Nasal Formulations of Metoclopramide" pertaining to the company's commercially available and FDA-approved
nasal formulation of metoclopramide, Gimoti.This new patent, issued on November 14, 2023, provides Evoke with additional intellectual property protections with claims to metoclopramide being delivered intranasally, amongst others. Evoke continues to see significant commercial value, particularly with the rising popularity of GLP-1 agonist
medications for diabetes which are potentially unmasking gastroparesis (stomach paralysis) in larger groups of patients, as per pharmabiz.Gimoti is the only non-oral
outpatient medication approved for the treatment of acute and recurring diabetic gastroparesis. Because gastroparesis causes pills to be absorbed in an unpredictable manner, the option to take the drug non-orally is critical. Pills may linger in the stomach instead of being transported into the intestines for absorption, or they may not be absorbed at all owing to one of the disease's primary symptoms, vomiting.“We continue to witness the significance of Gimoti in the marketplace through various validation points, including patient and
market data growing revenues, and a robust stream of patent protections. We are thrilled to continue providing patients a life-changing experience with diabetic gastroparesis treatment and bolster the already promising commercial opportunity for Gimoti,†commented Matt D’Onofrio, president and COO of Evoke Pharma.Gimoti is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
, CDSCO.jpg)
